Covid Researchers Icon, PRA Health Join in $12 Billion Deal
- Icon has supported Pfizer, BioNTech global vaccine studies
- PRA Health also involved in pandemic-related research
Photographer: SOPA Images/LightRocket/Getty Images
This article is for subscribers only.
Icon Plc agreed to buy PRA Health Sciences Inc. in a $12 billion cash and stock deal that combines two research providers supporting Covid vaccine and treatment trials.
Both companies help run outsourced clinical trials for drugmakers and medical device developers, a business that’s been caught up in the global rush to immunize populations against the coronavirus.